US 12,246,020 B2
Heterocyclic compounds, preparation methods and uses thereof
Xing Dai, Shanghai (CN); Yueheng Jiang, Shanghai (CN); and Yanqin Liu, Shanghai (CN)
Assigned to InventisBio Co., Ltd., Shanghai (CN)
Filed by InventisBio Co., Ltd., Shanghai (CN)
Filed on Nov. 22, 2023, as Appl. No. 18/517,156.
Application 18/517,156 is a continuation of application No. 17/591,816, filed on Feb. 3, 2022, granted, now 11,865,115.
Application 17/591,816 is a continuation of application No. 17/172,984, filed on Feb. 10, 2021, granted, now 11,241,437, issued on Feb. 8, 2022.
Application 17/172,984 is a continuation of application No. PCT/CN2020/137276, filed on Dec. 17, 2020.
Claims priority of application No. PCT/CN2019/126230 (WO), filed on Dec. 18, 2019.
Prior Publication US 2024/0156820 A1, May 16, 2024
Int. Cl. C07D 487/04 (2006.01); A61K 31/505 (2006.01); A61K 31/519 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07D 471/04 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 45/06 (2013.01); C07D 471/04 (2013.01); C07B 2200/13 (2013.01)] 20 Claims
 
1. A crystalline form of Compound 2:

OG Complex Work Unit Chemistry
wherein the crystalline form is Form B, characterized by an X-ray powder diffraction (XRPD) pattern (i) having all of the following peaks 6.2, 12.6, 14.8, 19.0, and 19.8 degrees 2 theta, ±0.2°; and (ii) having at least one of the following peaks: 14.5, 17.8, 21.4, 26.3, 31.9 and 38.6 degrees 2 theta, ±0.2°.